Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Relapsed/Refractory or Ineligible Acute Myeloid Leukemia
NCT01361334Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Jun 2011
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in acute myeloid leukemia (AML), sponsored by Universitätsklinikum Münster. Started Jun 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01361334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361334.